Showing papers by "Roussel Uclaf published in 1984"

Enzymic hydrolysis of erythromycin by a strain of Escherichia coli. A new mechanism of resistance.

Abstract: Escherichia coli BM2195 is highly resistant to erythromycin by inactivation of the antibiotic. We have determined the structure of the modified antibiotic by physico-chemical techniques including mass spectrometry, infrared spectrophotometry, 13C nuclear magnetic resonance, and circular dichroism. The results obtained indicate that E. coli BM2195 resists erythromycin by the production of an erythromycin esterase which hydrolyzes the lactone ring of the antibiotic.

Experimental Brain Ischemia: Neuron‐Specific Enolase Level in Cerebrospinal Fluid as an Index of Neuronal Damage

Abstract: Levels of neuron-specific enolase (NSE) were measured in rat CSF following occlusion of the four major arteries to the brain for 10, 20, or 30 min. In the CSF of rats submitted to 30 min of total ischemia, an up to ninefold increase of NSE level occurred within the first few hours and then slowly diminished. Significant levels were seen for as long as 8 days. Histological observations 3 days after ischemia showed neuronal loss as well as neu- ronal damage in several forebrain regions such as hippocampus, striatum, and thalamus. Ischemia was followed by transient decreases in exploration behavior and neurological states that were no longer visible 24 h later. After 10 or 20 min ischemia, NSE levels were increased to a lesser degree and fewer damaged neurons were observed. The positive correlation between duration of ischemia and amount of NSE release in CSF indicates that the measurement of NSE in the CSF is a sensitive and reliable index of neuronal lesions.

The pure antiandrogen RU 23908 (Anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review

Abstract: The nonsteroidal antiandrogen RU 23908 ( Anandron ) weakly interacts with the prostatic cytosolic androgen receptor and shows a fast dissociation rate. When administered to immature castrated rats up to the daily dose of 100 mg/kg, it is devoid of any androgenic activity but efficiently blocks the growth-promoting activity of androgens on ventral prostate and seminal vesicle weight, thus showing the characteristics of a pure antiandrogen. In intact animals, on the other hand, the antiandrogen administered alone exerts only a partial inhibition of prostate and seminal vesicle weight. This is due to the property of the pure antiandrogen to neutralize the inhibitory feedback effect of androgens at the pituitary level on the LH responsiveness to LHRH, as illustrated in vitro in rat anterior pituitary cells in culture as well as in vivo in intact and castrated animals. In intact animals, neutralization of the inhibitory feedback action of endogenous androgens leads to an increased LH and testosterone secretion, which partly overcomes the direct action of the antiandrogen at the level of the prostate and seminal vesicles. In fact, the plasma testosterone concentration is more than doubled 6 hr after the administration of 10 mg of RU 23908 while plasma LH and testosterone levels are increased by 7- and 17-fold, respectively, after 14 days of similar daily treatment. Efficient neutralization of the androgenic action at the prostatic level in intact animals thus requires prevention of this escape phenomenon through inhibition of LH secretion. Although inhibition of LH release can be achieved by estrogen and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.

Animal models for hormone-dependent human breast cancer: relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate

Abstract: The present study shows that canine and feline mammary tumors, like human breast tumors, can be polyreceptive, i.e., they can contain estrogen (ER), progestin (PR), androgen, glucocorticoid, and/or mineralocorticoid cytosol receptors. Furthermore, a follow-up of 45 bitches with mammary carcinoma has indicated that the survival rate is significantly higher in animals with receptor-rich (ER and/or PR) tumors. This indicates that these canine mammary tumors should be evaluated further for their suitability as an animal model for hormone-dependent human breast carcinoma.

Immunological activities of RU-41740, a glycoproteic extract from Klebsiella pneumoniae. I.--Activation of murine B cells and induction of interleukin-1 production by macrophages.

Abstract: Summary RU-41740, a glycoprotein extract from Klebsiella pneumoniae K2O1 strain, is an immunomodulating compound which has been shown to reduce infectious episodes in immunodeficient patients. Data from preliminary experimental designs suggested that RU-41740 could affect several target cells, such as T cells, B cells and macrophages. In the present report, we show that RU-41740 is a selective B-lymphocyte activator. It induces blast transformation in Nude mouse spleen cell cultures and in B-cell-enriched fractions obtained from normal mice. It does not activate T lymphocytes to proliferate. Activation of mouse B lymphocytes by RU-41740 is not affected by removal of adherent cells. RU-41740 also activates immunoglobulin secrection by murine B lymphocytes. Incubating spleen cells from C3H/HeJ mice with RU-41740 results in cell proliferation and activation of antibody-forming cells. This suggests that B-cell activation is not due to LPS contamination. Other experiments show that RU-41740 can also trigger mouse macrophages to produce interleukin-1 activity. Indeed, supernatants from peritoneal adherent cells incubated in the presence of RU-41740 can stimulate blastogenesis in thymocytes from C3H/HeJ mice. Thus, B-cell activation and IL-1 production by macrophages could constitute two additive mechanisms involved in immunomodulation induced by RU-41740.

Derivatives of omega mercaptopropanamides, and their homologues, process for their preparation, their use as medicines, compositions containing them and intermediates obtained

Abstract: For the Contracting States : BE CH DE FR GB IT LI LU NL SE 1. Compounds with the formula (I) : see diagramm : EP0115997,P26,F1 in which R1 represents a hydrogen atom or a see diagramm : EP0115997,P26,F2 radical, R'1 being an alkyl radical containing from 1 to 5 carbon atoms or an aryl radical possibly substituted by a hydroxy radical, an alkyl radical containing from 1 to 5 carbon atoms, an alkoxy radical containing from 1 to 5 carbon atoms, a nitro radical or a halogen atom, n represents a whole number able to vary from 1 to 5, R2 represents a hydrogen atom, an alkyl radical containing from 1 to 5 carbon atoms, an aryl or arylalkyl radical containing from 6 to 15 carbon atoms, possibly substituted by an alkyl radical containing from 1 to 5 carbon atoms, an alkoxy radical containing from 1 to 5 carbon atoms, a hydroxyl radical, a halogen atom or a trifluoromethyl radical, R3 represents a heterocyclic radical chosen from the following radicals :- thiazolyl, 4,5-dihydrothiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidyl, tetrazolyl, benzimidazolyl, benzothiazolyl or benzoxazolyl, possibly substituted by an alkyl radical containing from 1 to 5 carbon atoms or R3 represents a hydrogen atom, a phenyl radical possibly substituted by one or more radicals chosen from the group constituted by alkyl radicals containing from 1 to 5 carbon atoms, alkoxy radicals containing from 1 to 5 carbon atoms, a hydroxyl radical, a nitro radical, halogen atoms, a trifluoromethyl radical, a carboxymethyl radical, alkoxy carbonylmethyl radicals in which the alkoxy radical contains from 1 to 5 carbon atoms, aralkyloxy radicals containing from 7 to 15 carbon atoms and the radicals : see diagramm : EP0115997,P27,F3 in which X and X', identical or different, represent a hydrogen atom or an alkyl radical containing from 1 to 5 carbon atoms, R3 however not being able to represent a phenyl radical, not substituted or substituted by one or more radicals chosen from the group constituted by alkyl radicals containing from 1 to 5 carbon atoms, alkoxy radicals containing from 1 to 5 carbon atoms, and halogen atoms, when R2 represents a hydrogen atom and when n is equal to 1 or 2, and R3 not being able to represent a phenyl radical substituted by a carboxymethyl radical when R2 represents a methyl radical and when n is equal to 1, as well as their addition salts with acids and bases. For the Contracting State : AT 1. Process for preparing compounds with the formula (I) : see diagramm : EP0115997,P28,F1 in which R1 represents a hydrogen atom or a see diagramm : EP0115997,P28,F2 radical, R'1 being an alkyl radical containing from 1 to 5 carbon atoms or an aryl radical possibly substituted by a hydroxy radical, an alkyl radical containing from 1 to 5 carbon atoms, an alkoxy radical containing from 1 to 5 carbon atoms, a nitro radical or a halogen atom, n represents a whole number able to vary from 1 to 5, R2 represents a hydrogen atom, an alkyl radical containing from 1 to 5 carbon atoms, an aryl or arylalkyl radical containing from 6 to 15 carbon atoms, possibly substituted by an alkyl radical containing from 1 to 5 carbon atoms, an alkoxy radical containing from 1 to 5 carbon atoms, a hydroxyl radical, a halogen atom or a trifluoromethyl radical, R3 represents a heterocyclic radical chosen from the following radicals :- thiazolyl, 4,5-dihydrothiazolyl, pyridinyl, oxazolyl, isoxazolyl, imidazolyl, pyrimidyl, tetrazolyl, benzimidazolyl, benzothiazolyl or benzoxazolyl, possibly substituted by an alkyl radical containing from 1 to 5 carbon atoms or R3 represents a hydrogen atom, a phenyl radical possibly substituted by one or more radicals chosen from the group constituted by alkyl radicals containing from 1 to 5 carbon atoms, alkoxy radicals containing from 1 to 5 carbon atoms, a hydroxyl radical, a nitro radical, halogen atoms, a trifluoromethyl radical, a carboxymethyl radical, alkoxy carbonylmethyl radicals in which the alkoxy radical contains from 1 to 5 carbon atoms, aralkyloxy radicals containing from 7 to 15 carbon atoms and the radicals : see diagramm : EP0115997,P29,F3 in which X and X', identical or different, represent a hydrogen atom or an alkyl radical containing from 1 to 5 carbon atoms, R3 however not being able to represent a phenyl radical, not substituted or substituted by one or more radicals chosen from the group constituted by alkyl radicals containing from 1 to 5 carbon atoms, alkoxy radicals containing from 1 to 5 carbon atoms, and halogen atoms, when R2 represents a hydrogen atom and when n is equal to 1 or 2, and R3 not being able to represent a phenyl radical substituted by a carboxymethyl radical when R2 represents a methyl radical and when n is equal to 1, as well as their addition salts with acids and bases, characterized in that : - to prepare compounds with the formula (I) in which R1 , R2 and R3 have the previously given significance and in which n=1, as well as their addition salts with acids and bases, and acid with the formula (II) : see diagramm : EP0115997,P29,F4 in which R'1 and R2 have the significances already indicated, or a functional derivative of this acid, is submitted to the action of a product with the formula (III) : H2 N-R3 in which R3 has the significance already indicated, so as to obtain a product with the formula (I) in which : see diagramm : EP0115997,P29,F5 R'1 as well as R2 and R3 have the significances already indicated and in which n=1, which product with the formula (I), if necessary or desired, is saponified, so as to obtain a product with the formula (I) in which R1 represents a hydrogen atom, which products with the formula (I) are submitted, if desired, to the action of a base or an acid so as to form the corresponding salts ; - to prepare compounds with the formula (I) in which R1 , R2 and R3 have the previously given significance and in which n is a whole number varying from 1 to 5, as well as their addition salts with acids and bases, an acid with the formula (IV) : see diagramm : EP0115997,P29,F6 in which X1 is a halogen atom and in which n and R2 have the significances given above, or a functional derivative of this acid, is submitted to the action of a product with the previous formula (III) (NH2 -R3 ), so as to obtain a product with the formula (V) : see diagramm : EP0115997,P29,F7 in which X1 , n, R2 and R3 have the previosu significances, which is submitted to the action of the anion of a thioacid with the formula (VI) : see diagramm : EP0115997,P30,F8 in which R'1 keeps its significance, so as to obtain a product with the formula (I) in which r1 = R'1 see diagramm : EP0115997,P30,F9 n represents a whole number able to vary from 1 to 5 and in which R'1 , R2 and R3 have the significances given above, which product with the formula (I), if necessary or desired, is saponified, so as to obtain a product with the formula (I) in which R1 represents a hydrogen atom, which products with the formula (I) are submitted, if desired, to the action of an acid or of a base so as to form the corresponding salts.

Effects of progestins and antiprogestins on mitochondria in uterine glandular cells in the rat. A quantitative investigation.

Abstract: The administration of progesterone to ovariectomized rats induces an increase in the volume density (Vv) of the mitochondria and the appearance of giant mitochondria in the uterine glandular cells. This experimental model, including a stereological analysis, allowed us to investigate and quantify a direct effect of progesterone on a well-defined cellular structure without the intervention of estrogen in a priming phase. Synthetic compounds, promegestone, gestrinone and RU 38486, were tested in this model either in place of progesterone or simultaneously with progesterone. The potent progestomimetic activity of promegestone was confirmed by the proliferation of giant mitochondria and a high Vv value for the mitochondria, the two other compounds being inactive even at higher doses. At lower doses, gestrinone and RU 38486 partially inhibit the action of progesterone and at higher doses they both show a complete antagonist effect by preventing the development of the mitochondria.

Process for the preparation of 21-hydroxy-20-keto-delta__ -steroids and new intermediate compounds formed in this process

Abstract: The invention relates to a new process for the preparation of 20-keto-.DELTA.16 steroids wherein a 17-isocyanosulfonylmethylene steroid is converted in one step into the new 20-isocyano-20-sulfonyl-.DELTA.16 steroid using an alkylating agent such as methylio-dide. The resulting steroid is hydrolyzed in a subsequent step to the corresponding 20-keto-.DELTA.16 steroid. The final products are suitable starting compounds for the preparation of therapeuti-cally useful steroids, comprising pregnanes and, particularly, progesterone derivatives.

3-amino-2-oxo-azetidine derivatives containing in position 1 a nitrogen heterocyclic radical, process for their preparation, their use as therapeutical agents and intermediates for their preparation

Abstract: 1. Claims : For the contracting states : BE, SE, CH, DE, FR, GB, IT, LI, LU, NL Products of general formula (I) : see diagramm : EP0114128,P43,F6 in which R represents a hydrogen atom, an alkyl, alkenyl or alkynyl radical having at the most 12 carbon atoms, optionally substituted by one or more radicals chosen from carboxy radicals, optionally salified or esterified ; amino, methylamino, dimethylamino and diethylamino radicals ; the phenyl radical optionally substituted by one or more radicals chosen from the following radicals : hydroxy, methyl, methoxy, chloro, bromo, fluoro ; fluoro, chloro, bromo or iodo radicals ; nitrile, CONH2 or CONH SO2 R" radicals in which R" represents an alkyl radical having from 1 to 4 carbon atoms ; a phenyl radical, an amino, methyl or dimethylamino radical ; a heterocyclic amino radical chosen from piperidino, morpholino piperazino or 4-ethyl-2,3-dioxo-1-piperazino radicals ; - a cycloalkyl radical having from 3 to 8 carbon atoms or a radical : see diagramm : EP0114128,P44,F1 salified or esterified, in which nc represents a whole number from 0 to 5, - one of the following radicals : acetyl, propionyl or benzoyl, carbamoyl, dimethylamino carbonyl, phenyl or benzyl optionally substituted by alkyl, alkoxy or halogen ; R1 represents a hydrogen atom, an alkyl, alkenyl, alkynyl or thioalkyl radical having a the most 12 carbon atoms, optionally substituted by one or more radicals chosen from azido or alkylthio radicals having from 1 to 4 carbon atoms or a phenylthio radical, optionally salified or esterified carboxy radicals, amino, methylamino, dimethylamino or diethylamino radicals, the phenyl radical, optionally substituted by one or more radicals chosen from hydroxy, halogeno, trifluoromethyl, amino, alkyl or alkoxy radicals having from 1 to 4 carbon atoms ; fluoro, chloro, bromo or iodo radicals, nitrile, CONH2 or CONH SO2 R" radicals in which R" represents an alkyl radical having from 1 to 4 carbon atoms, a phenyl radical, an amino, methyl or dimethylamino radical, a heterocyclic amino radical chosen from piperidino, morpholino, piperazino or 4-ethyl-2,3-dioxo-1-piperazino radicals ; a heterocyclic aryl radical chosen from the following radicals : thienyl, furyl, pyrannyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridinyl or pyrimidinyl ; and the following radicals : acetoxy, propionyloxy, benzoyloxy, acetylamino, benzylcarbonyl, carbamoyloxy, methylaminocarbonyloxy or dimethylaminocarbonyloxy, acetyl, propionyl, and benzoyl, - a free, esterified or salified carboxy radical, - a phenyl radical optionally substituted by one of the following radicals : alkyl, trifluoromethyl, alkoxy, alkylthio, halogen, hydroxyl, amino or hydroxylakyl, a heterocyclic radical chosen from the following radicals : thienyl, furyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolinyl, imidazolyl, triazolyl, tetrazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, triazinyl optionally substituted by an alkyl, carboxy, carboxy alkyl, aminoalkyl or dialkylaminoalkyl radical, - an acetyl, propionyl, n-butyryl or benzoyl radical, optionally substituted by alkoxy or hydroxy, - a carbamoyl, methyl or dimethylcarbamoyl radical, - a azido radical. R2 represents a nitrogen-containing heterocycle optionally substituted by one or more of the radicals chosen from the group formed by the following radicals : nitro, carboxy, CF3 , nitrile, halogen, sulpho, alkylsulpho, (CH2 )n SO3 H, (CH2 )n NHSO3 H, (CH2 )n SO2 NH2 , (CH2 )n CO2 H, in which n represents a whole number from 1 to 4 and containing at least one acid hydrogen, X represents a CH radical or a nitrogen atom, the wavy lines indicate that the OR radical can exist in cis or trans form or in the form of a cis-trans mixture, the products of formula (I) being in racemic or optically active form, as well as the salts of the products of formula (I) withthe bases and acids. 1. Claims : For the contracting state AT Process for preparing the products of general formula (I) : see diagramm : EP0114128,P48,F3 in which R represents a hydrogen atom, an alkyl, alkenyl or alkynyl radical having at the most 12 carbon atoms, optionally substituted by one or more radicals chosen from carboxy radicals, optionally salified or esterified ; amino, methylamino, dimethylamino and diethylamino radicals ; the phenyl radical optionally substituted by one or more radicals chosen from the following radicals : hydroxy, methyl, methoxy, chloro, bromo, fluoro ; fluoro, chloro, bromo or iodo radicals ; nitrile, CONH2 or CONH SO2 R" raidcals in which R" represents an alkyl radical having from 1 to 4 carbon atoms ; a phenyl radical ; an amino, methyl or dimethylamino radical ; a heterocyclic amino radical chosen from piperidino, morpholino piperazino or 4-ethyl-2,3-dioxo-1-piperazino radicals ; - a cycloalkyl radical having from 3 to 8 carbon atoms or a radical : see diagramm : EP0114128,P48,F1 salified or esterified, in which nc represents a whole number from 0 to 5, - one of the following radicals : acetyl, propionyl, or benzoyl, carbamoyl, dimethylamino carbonyl, phenyl or benzyl optionally substituted by alkyl, alkoxy or halogen ; R1 represents a hydrogen atom, an alkyl, alkenyl, alkynyl or thioalkyl radical having at the most 12 carbon atoms, optionally substituted by one or more radicals chosen from azido or alkylthio radicals having from 1 to 4 carbon atoms or a phenylthio radical, optionally salified or esterified carboxy radicals, amino, methylamino, dimethylamino or diethylamino radicals, the phenyl radical, optionally substituted by one or more radicals chosen from hydroxy, halogeno, trifluoromethyl, amino, alkyl or alkoxy radicals having from 1 to 4 carbon atoms ; fluoro, chloro, bromo or iodo radicals, nitrile, CONH2 or CONH SO2 R" which R" represents an alkyl radical having from 1 to 4 carbon atoms, a phenyl radical, an amino, methyl or dimethylamino radical, a heterocyclic amino radical chosen from piperidino, morpholino, piperazino or 4-ethyl-2,3-dioxo-1-piperazino radicals ; a heterocyclic aryl radical chosen from the following radicals : thienyl, furyl, pyrannyl, thiazolyl, thiadiazolyl, oxazolyl, oxadiazolyl, pyridinyl or pyrimidinyl ; and the following radicals : acetoxy, propionyloxy, benzoyloxy, acetylamino, benzylcarbonyl, carbamoyloxy, methylaminocarbonyloxy or dimethylaminocarbonyloxy, acetyl, propionyl, and benzoyl, - a free, esterified or salified carboxy radical, - a phenyl radical optionally substituted by one of the following radicals : alkyl, trifluoromethyl, alkoxy, alkylthio, halogen, hydroxyl, amino or hydroxyalkyl, a heterocyclic radical chosen from the following radicals : thienyl, furyl, pyrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolinyl, imidazolyl, triazolyl, tetrazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, triazinyl optionally substituted by an alkyl, carboxy, carboxy alkyl, aminoalkyl or dialkylaminoalkyl radical, - an acetyl, propionyl, n-butyryl or benzoyl radical, optionally substituted by alkoxy or hydroxy, - a carbamoyl, methyl or dimethylcarbamoyl radical, - an azido radical. R2 represents a nitrogen-containing heterocycle optionally substituted by one or more of the radicals chosen from the group formed by the following radicals : nitro, carboxy, CF3 , nitrile, halogen, sulpho, alkylsulpho, (CH2 )n SO3 H, (CH2 )n NHSO3 H, (CH2 )n SO2 NH2 , (CH2 )n CO2 H, in which n represents a whole number from 1 to 4 and containing at least one acid hydrogen, X represents a CH radical or a nitrogen atom, the wavy lines indicate that the OR radical can exist in cis or trans form or in the form of a cis-trans mixture, the products of formula (I) being in racemic or optically active form, as well as the salts of the products of formula (I) with the acids and bases, characterized in that a product of formula (II) : see diagramm : EP0114128,P49,F1 cis or trans, racemic or optically active, in which formula either R1 p represents R1 , R1 having the previously indicated significance, or R1 p represents the substituent R1 in which the reactive functions are protected and either R2 p represents R2 , R2 having the previously indicated significance, or R2 p represents the substituent R2 in which the reactive functions are protected, is treated with a product of formula (III) : see diagramm : EP0114128,P49,F3 syn or anti, in which Rb represents a hydrogen atom or a protector group of the amino radical and Rp represents a protector group of the hydroxyl radical or Rp represents R, R having the significance indicated in claim 1, or Rp represents a radical R in which the reactive functions are protected, so as to obtain a product of formula (IV) : see diagramm : EP0114128,P49,F5 syn or anti, racemic or optically active, in which Rp, R1 p, R2 p and Rb have the previous significance, which product is submitted, if necessary and if desired, to any one of the following reactions, in any order : a) cleavage by hydrolysis, hydrogenolysis or by the action of the thiourea of the protector group or groups which can be represented by Rb and Rp or can be contained in Rp, R1 p and R2 p ; b) esterification or salification of the carboxy or sulpho radicals which can be contained in the radicals Rp, R1 p and R2 p ; c) salification by an acid of the amino radical or radicals ; d) resolution of the molecule so as to obtain an optically active product.

Derivatives of 4-phenyl-4-oxo-buten-2-oic acid and therapeutic use thereof

Abstract: Compounds of the formula (I): ##STR1## in which R 1 represents alkyl containing from 1 to 18 carbon atoms, R 2 represents hydrogen or alkyl containing from 1 to 8 carbon atoms and R represents hydrogen or alkyl containing from 1 to 8 carbon atoms, as well as the alkali metal, alkaline-earth metal or amine salts thereof, in which R represents hydrogen. Also, method of preparing same, compositions containing same and therapeutic treatment therewith.

Compositions used in dietetics, reanimation and therapeutics, containing a protein fraction based on 3 types of minipeptides, and their applications

Abstract: 1. Compositions containing glucides, vitamins, mineral salts, a lipid fraction and a protein fraction, characterized in that the protein fraction contains the following 3 types of minipeptides : - lactoserum minipeptides, - total casein minipeptides, - casein minipeptides without phosphopeptides.

2-substituted imidazo[1,2-c]pyrimidines having anxiolytic properties

Abstract: Novel imidazo[1,2-c]pyrimidines of the formula ##STR1## wherein R is an aryl of 6 to 12 carbon atoms, R 1 is selected from the group consisting of hydrogen and alkyl, alkoxy and alkylthio of 1 to 5 carbon atoms when R 2 and R 3 together form a carbon-nitrogen bond or R 1 and R 2 together are ═0 when R 3 is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms and alkenyl of 2 to 5 carbon atoms, R 4 is selected from the group consisting of alkoxy and alkylthio of 1 to 5 carbon atoms, R 5 is selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts having anxiolytic properties.